Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial

There is no available effective systemic treatment for patients with advanced hepatocellular carcinoma (HCC) who are intolerant of sorafenib or who have disease that has progressed on sorafenib. In Phase I and II studies, tivantinib (ARQ 197), an oral inhibitor of MET, demonstrated promising antitum...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Hepat Oncol
Main Authors: Rimassa, Lorenza, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Finn, Richard S, Raoul, Jean-Luc, Schwartz, Lawrence H, He, Aiwu Ruth, Trojan, Joerg, Peck-Radosavljevic, Markus, Abbadessa, Giovanni, Goldberg, Terri, Santoro, Armando, Bruix, Jordi
Format: Artigo
Sprog:Inglês
Udgivet: Future Medicine Ltd 2014
Fag:
Clinical Trial Protocol
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6095177/
https://ncbi.nlm.nih.gov/pubmed/30190953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep.14.3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker